TCP
CYCN icon

Tyndall Capital Partners’s Cyclerion Therapeutics CYCN Stock Holding History

Tyndall Capital Partners’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-155,187
Closed -$452K – 1
2025
Q2 		$452K Sell
155,187
-9,590
-6% -$28.6K 100% 1
2025
Q1 		$412K Hold
164,777
– – 100% 1
2024
Q4 		$531K Hold
164,777
– – 100% 1
2024
Q3 		$427K Hold
164,777
– – 100% 1
2024
Q2 		$379K Hold
164,777
– – 100% 1
2024
Q1 		$527K Buy
164,777
+348
+0.2% +$1.11K 100% 1
2023
Q4 		$551K Buy
164,429
+16,717
+11% +$48.3K 100% 1
2023
Q3 		$505K Buy
+147,712
New +$533K 100% 1

Other funds holding CYCN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Tyndall Capital Partners's CYCN Position: Q3 2025 in Review

Tyndall Capital Partners sold out of Cyclerion Therapeutics (CYCN) in Q3 2025, closing a stake of 155,187 shares — an estimated $452K sold.

Tyndall Capital Partners first reported a position in CYCN in Q3 2023 and held it in 8 quarters. The position peaked at $551K in Q4 2023. 17 funds tracked by Wall St. Rank hold CYCN as of Q3 2025.

  • Tyndall Capital Partners reported no remaining Cyclerion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tyndall Capital Partners sold 155,187 Cyclerion Therapeutics shares in Q3 2025, an estimated $452K.
  • Tyndall Capital Partners first reported a position in Cyclerion Therapeutics in Q3 2023 and held it in 8 quarters.
  • Tyndall Capital Partners's Cyclerion Therapeutics position peaked at $551K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2025.

Based on Tyndall Capital Partners's 13F filing for Q3 2025.